» Articles » PMID: 26457057

Lipoxins: Nature's Way to Resolve Inflammation

Overview
Journal J Inflamm Res
Publisher Dove Medical Press
Date 2015 Oct 13
PMID 26457057
Citations 104
Authors
Affiliations
Soon will be listed here.
Abstract

An effective host defense mechanism involves inflammation to eliminate pathogens from the site of infection, followed by the resolution of inflammation and the restoration of tissue homeostasis. Lipoxins are endogenous anti-inflammatory, pro-resolving molecules that play a vital role in reducing excessive tissue injury and chronic inflammation. In this review, the mechanisms of action of lipoxins at the site of inflammation and their interaction with other cellular signaling molecules and transcription factors are discussed. Emphasis has also been placed on immune modulatory role(s) of lipoxins. Lipoxins regulate components of both the innate and adaptive immune systems including neutrophils, macrophages, T-, and B-cells. Lipoxins also modulate levels of various transcription factors such as nuclear factor κB, activator protein-1, nerve growth factor-regulated factor 1A binding protein 1, and peroxisome proliferator activated receptor γ and control the expression of many inflammatory genes. Since lipoxins and aspirin-triggered lipoxins have clinical relevance, we discuss their important role in clinical research to treat a wide range of diseases like inflammatory disorders, renal fibrosis, cerebral ischemia, and cancer. A brief overview of lipoxins in viral malignancies and viral pathogenesis especially the unexplored role of lipoxins in Kaposi's sarcoma-associated herpes virus biology is also presented.

Citing Articles

Resolving lipoxin A: Endogenous mediator or exogenous anti-inflammatory agent?.

McGuffee R, Luetzen M, Ford D J Lipid Res. 2024; 66(2):100734.

PMID: 39724959 PMC: 11786773. DOI: 10.1016/j.jlr.2024.100734.


Regulated Cell Death of Alveolar Macrophages in Acute Lung Inflammation: Current Knowledge and Perspectives.

Xia S, Gu X, Wang G, Zhong Y, Ma F, Liu Q J Inflamm Res. 2024; 17:11419-11436.

PMID: 39722732 PMC: 11669335. DOI: 10.2147/JIR.S497775.


Regulation of disease-associated microglia in the optic nerve by lipoxin B and ocular hypertension.

Maurya S, Lin M, Karnam S, Singh T, Kumar M, Ward E Mol Neurodegener. 2024; 19(1):86.

PMID: 39568070 PMC: 11580672. DOI: 10.1186/s13024-024-00775-z.


Understanding dental pulp inflammation: from signaling to structure.

Pohl S, Akamp T, Smeda M, Uderhardt S, Besold D, Krastl G Front Immunol. 2024; 15:1474466.

PMID: 39534600 PMC: 11554472. DOI: 10.3389/fimmu.2024.1474466.


Effect of pioglitazone on inflammatory response and clinical outcome in T2DM patients with COVID-19: a randomized multicenter double-blind clinical trial.

Baagar K, Alessa T, Abu-Farha M, Abubaker J, Alhumaidi H, Franco Ceruto J Front Immunol. 2024; 15:1369918.

PMID: 39308871 PMC: 11412854. DOI: 10.3389/fimmu.2024.1369918.


References
1.
Serhan C . Lipoxin metabolism by human promyelocytic leukemia (HL-60) cells. Adv Exp Med Biol. 1997; 400B:641-6. View

2.
Levy B, Serhan C . Exploring new approaches to the treatment of asthma: potential roles for lipoxins and aspirin-triggered lipid mediators. Drugs Today (Barc). 2003; 39(5):373-84. DOI: 10.1358/dot.2003.39.5.740217. View

3.
Paul A, Sharma-Walia N, Chandran B . Targeting KSHV/HHV-8 latency with COX-2 selective inhibitor nimesulide: a potential chemotherapeutic modality for primary effusion lymphoma. PLoS One. 2011; 6(9):e24379. PMC: 3184084. DOI: 10.1371/journal.pone.0024379. View

4.
Querfurth H, LaFerla F . Alzheimer's disease. N Engl J Med. 2010; 362(4):329-44. DOI: 10.1056/NEJMra0909142. View

5.
Medina Avalos M, Orea Solano M . [Macrophages in asthma]. Rev Alerg Mex. 1998; 44(5):135-9. View